Biological
GI-6301 clinical trials
Also written GI-6301.
- studies test it
- 18
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Development codes
- GI-6301
- 16
Studies by the year they started
18 studies that test it; most in 2018 (10)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2017 | 6 |
| 2018 | 10 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 17
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 1
ImmunityBio, Inc. (16) · NantCell, Inc. (1) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Nogapendekin alfa inbakicept (16) · ETBX-051 (16) · ETBX-061 (16) · Avelumab (16) · Cyclophosphamide (15) · Fluorouracil (15) · Leucovorin (14) · Paclitaxel (14)
Studies
Open first, then newest update. How each study uses GI-6301 is read from its arms, and is right about nine times in ten.
Testing it · 18
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169764Written as GI-6301
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03175666Written as GI-6301
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03563144Written as GI-6301
- QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnPhase 2ImmunityBio, Inc.NCT03574649Written as GI-6301
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnPhase 1/2ImmunityBio, Inc.NCT03647423Written as GI-6301
- QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167164Written as GI-6301
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197584Written as GI-6301
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169738Written as GI-6301
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167177Written as GI-6301
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169777Written as GI-6301
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197571Written as GI-6301
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03554109Written as GI-6301
- QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03586869Written as GI-6301
- QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedPhase 1/2ImmunityBio, Inc.NCT03387085Written as GI-6301
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/2ImmunityBio, Inc.NCT03387111Written as GI-6301
- QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine ChordomaCompletedPhase 2NantCell, Inc.NCT02383498Written as GI-6301 Vaccine (Yeast- Brachyury)
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnPhase 1/2ImmunityBio, Inc.NCT03563170Written as GI-6301
- Cancer Vaccine Targeting Brachyury Protein in TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01519817Written as GI-6301 (Yeast Brachyury Vaccine)
Given in every arm · 1 — GI-6301 is usual care beside what is tested
Codes
What other systems call GI-6301 · ClinicalTrials.gg INT016053
- UNII (FDA) B0L24T8TB7GI-6301One source FDA
- NCI Thesaurus C106267Brachyury-expressing Yeast Vaccine GI-6301One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B0L24T8TB7 | GI-6301 | One source FDA |
| NCI Thesaurus | C106267 | Brachyury-expressing Yeast Vaccine GI-6301 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.